To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business days. This requirement was met on April 16, 2024.
Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.